News
Covid, Moderna and FDA
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry. The tumultuous ...
3d
Barchart on MSNThe Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results